Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Elena Noguera

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Hematology|May 18, 2011
Non-MALT marginal zone lymphomaCatherine Thieblemont, Frederic Davi, Maria-Elena Noguera, et al.
Haematologica|September 8, 2006
Telehematology: a pilot experience of cytological diagnosis of acute myeloid leukemia via the Internet. A GOELAMS studyVincent Leymarie, Georges Flandrin, Maria Elena Noguera, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphomaSophie Park, Maria-Elena Noguera, Josette Brière, et al.
European Journal of Haematology|May 6, 2015
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapyThomas Cluzeau, Eric Lippert, Jean-Michel Cayuela, et al.
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemiaMarjan Ertault-Daneshpouy, Maria Elena Noguera, Christian Gisselbrecht, et al.
Oncology (Williston Park, N.Y.)|April 12, 2012
Splenic marginal zone lymphoma: current knowledge and future directionsCatherine Thieblemont, Frederic Davi, Maria-Elena Noguera, et al.
The Journal of Clinical Investigation|December 25, 2010
Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patientsRaphael Ceccaldi, Delphine Briot, Jérôme Larghero, et al.
Leukemia & Lymphoma|November 12, 2013
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatmentJulien Lenglet, Catherine Traullé, Nicolas Mounier, et al.
Journal of Hematology & Oncology|January 29, 2016
GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathwaysLaura Guerenne, Stéphanie Beurlet, Mohamed Said, et al.
Oncotarget|September 18, 2015
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignanciesCarole Le Pogam, Satyananda Patel, Petra Gorombei, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Hematology|May 18, 2011
Non-MALT marginal zone lymphomaCatherine Thieblemont, Frederic Davi, Maria-Elena Noguera, et al.
Haematologica|September 8, 2006
Telehematology: a pilot experience of cytological diagnosis of acute myeloid leukemia via the Internet. A GOELAMS studyVincent Leymarie, Georges Flandrin, Maria Elena Noguera, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphomaSophie Park, Maria-Elena Noguera, Josette Brière, et al.
European Journal of Haematology|May 6, 2015
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapyThomas Cluzeau, Eric Lippert, Jean-Michel Cayuela, et al.
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemiaMarjan Ertault-Daneshpouy, Maria Elena Noguera, Christian Gisselbrecht, et al.
Oncology (Williston Park, N.Y.)|April 12, 2012
Splenic marginal zone lymphoma: current knowledge and future directionsCatherine Thieblemont, Frederic Davi, Maria-Elena Noguera, et al.
The Journal of Clinical Investigation|December 25, 2010
Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patientsRaphael Ceccaldi, Delphine Briot, Jérôme Larghero, et al.
Leukemia & Lymphoma|November 12, 2013
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatmentJulien Lenglet, Catherine Traullé, Nicolas Mounier, et al.
Journal of Hematology & Oncology|January 29, 2016
GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathwaysLaura Guerenne, Stéphanie Beurlet, Mohamed Said, et al.
Oncotarget|September 18, 2015
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignanciesCarole Le Pogam, Satyananda Patel, Petra Gorombei, et al.
Pageof 2